Mode
Text Size
Log in / Sign up

Patient Questions

Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.

Oncology

What are the survival rates for Acute Promyelocytic Leukemia treated with ATRA and ATO?

ATRA plus ATO for APL achieves 3-year overall survival of 95% and 10-year survival of ≥80%, with complete remission rates over 95%.

Oncology

What is the objective response rate for becotatug vedotin in recurrent head and neck cancer?

Becotatug vedotin showed a 20.9% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.

Oncology

Does having different receptors in metastatic breast cancer lesions affect how long I live?

Yes, different receptor types in metastatic breast cancer lesions are linked to different survival times, with hormone receptor-positive subtypes generally having longer survival…

Oncology

How does receptor discordance in metastatic breast cancer impact overall survival rates?

Receptor discordance in metastatic breast cancer is linked to worse overall survival, especially when hormone receptors are lost.

Oncology

Do hospital-acquired infections cause higher medical costs for discharged cancer center patients?

Yes, hospital-acquired infections significantly increase medical costs for discharged cancer center patients, including higher hospitalization costs and greater deficits under…

Oncology

What safety data exists for CAR-T cell therapy in B-cell malignancies?

CAR-T therapy for B-cell malignancies has transformed treatment but carries risks like B-cell aplasia and cytokine release syndrome. New approaches aim to improve safety while…

Oncology

Does the review mention any specific outcomes for pancreatic cancer CAR-T therapy?

Reviews indicate that while CAR-T therapy is established for B-cell malignancies, there are currently no specific outcomes or safety data available for its use in pancreatic…

Oncology

Can morning timing of immune checkpoint infusions improve survival outcomes in metastatic non-small cell lung cancer patients?

Morning timing of immune checkpoint infusions is linked to better survival in metastatic non-small cell lung cancer, while other new drugs like magrolimab have not shown clear…

Oncology

What new treatments for autoimmune diseases are emerging from cancer research?

Cancer research is producing new treatments for autoimmune diseases by adapting cell therapies like CAR-T cells and targeting shared inflammatory pathways such as IRAK4 and…

Oncology

Does having a larger baseline tumor burden affect survival in rare cancers treated with nivolumab?

In rare cancers treated with nivolumab plus ipilimumab, having a larger tumor burden at the start of treatment is linked to shorter overall survival.

Oncology

Can a nurse-led music intervention help my cancer-related cognitive impairment?

A nurse-led music intervention shows early promise for reducing feelings of cognitive impairment in colorectal cancer patients, though it is not yet proven for all cancer types.

Oncology

How does lifileucel TIL therapy work for patients with metastatic melanoma?

Lifileucel is a cell therapy that uses your own immune cells to fight metastatic melanoma after other treatments fail. It involves removing tumor cells, growing immune cells in a…

Oncology

Are there therapeutic opportunities for autoimmune disorders in cancer research?

Research shows that targeting shared molecular pathways like Siglec signaling, mitochondrial cell death, and immune metabolism offers new ways to treat both autoimmune disorders…

Oncology

What conditions besides cancer are linked to Siglec signaling pathways?

Siglec signaling pathways are linked to autoimmune and inflammatory disorders, neurodegeneration, and infections in addition to cancer.

Oncology

What are the safety profiles of different adjuvant chemotherapy regimens for early-stage breast cancer?

Adjuvant chemotherapy regimens for early-stage breast cancer have distinct safety profiles; TAC causes more febrile neutropenia, while AC→T leads to more neuropathy and hand-foot…

Oncology

Do activity pacing interventions show a significant effect on cancer-related fatigue?

Activity pacing interventions show a small but not statistically significant effect on cancer-related fatigue overall, but may significantly help patients undergoing chemotherapy.

Oncology

Does acupuncture significantly improve cancer-related fatigue levels for patients?

Yes, acupuncture appears to significantly improve cancer-related fatigue, with recent meta-analyses showing moderate benefit, though study quality is limited.

Oncology

Are PROTACs currently available as a treatment for my oncology condition?

PROTACs are not yet available as approved treatments for most oncology conditions, though one specific drug, vepdegestrant, is in clinical trials for advanced breast cancer.

Oncology

Does radical perineal prostatectomy cause less blood loss than the retropubic approach for localized prostate cancer?

Yes, radical perineal prostatectomy typically causes less blood loss than the retropubic approach for localized prostate cancer, based on direct comparative studies.

Oncology

How can artificial intelligence help patients with kidney cancer in surgery?

Artificial intelligence helps kidney cancer patients by improving tumor detection on scans, planning robotic surgeries, and predicting surgical outcomes to reduce complications.

Oncology

Are there new guidelines for kidney cancer based on recent 2025 trials?

Yes, the 2025 EAU guidelines update kidney cancer care with new recommendations on stereotactic body radiotherapy, adjuvant therapy, and systemic treatments for clear-cell and…

Oncology

Is camrelizumab associated with a higher risk of disease progression compared to pembrolizumab?

In nonsquamous advanced NSCLC, camrelizumab was linked to a higher risk of disease progression and death than pembrolizumab in second-line or later treatment, based on one…

Oncology

What does the research say about using chemotherapy versus immunotherapy for advanced Non-Small Cell Lung Cancer?

For advanced NSCLC, immunotherapy (especially pembrolizumab) is highly effective for high PD-L1 tumors, while chemotherapy remains a backbone; combining both may improve outcomes.

Oncology

Does real-world data support using pembrolizumab for my advanced Non-Small Cell Lung Cancer?

Yes, real-world data from over 17,500 patients shows pembrolizumab is effective as first-line treatment for advanced NSCLC with high PD-L1 (≥50%), with median overall survival of…

How this works

We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.

This is not medical advice. Always speak with your own doctor before making decisions about your health.